AbbVie’s Promising Phase 3 Study on Telisotuzumab Vedotin for NSCLC

Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.

AbbVie is conducting a Phase 3 clinical study titled ‘A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer.’ The study aims to evaluate the efficacy and safety of telisotuzumab vedotin compared to docetaxel in treating non-squamous non-small cell lung cancer (NSCLC) in adults who have undergone prior treatments. This research could significantly impact treatment protocols for NSCLC, a prevalent and challenging cancer type.

The intervention involves administering intravenous (IV) infusions of telisotuzumab vedotin, an investigational biological drug, every two weeks, compared to docetaxel, a standard chemotherapy drug given every three weeks. The goal is to assess changes in disease activity and adverse events.

This interventional study employs a randomized, parallel assignment model without masking, focusing primarily on treatment. Participants are randomly assigned to one of two groups to receive either telisotuzumab vedotin or docetaxel.

The study began on March 25, 2022, and is currently recruiting participants. The last update was submitted on June 23, 2025. These dates are crucial for tracking the study’s progress and estimating when results might influence market dynamics.

For investors, the study’s outcome could affect AbbVie’s stock performance, especially if telisotuzumab vedotin proves more effective than existing treatments. This could enhance AbbVie’s position in the oncology market, potentially impacting competitors focused on NSCLC therapies.

The study is ongoing, and further details can be accessed on the ClinicalTrials portal.